Chiesi Farmaceutici and Apotex (together with its American subsidiary, ApoPharma Usa), a company engaged in haematology and in the area of neurodegenerative diseases, have announced that they have signed an important agreement, in which Chiesi has acquired worldwide rights for Deferiprone, an iron chelator indicated for the treatment of patients with thalassaemia (including β-thalassaemia).
With the closing of the negotiations, the Deferiprone franchise will become part of the Chiesi portfolio dedicated to patients suffering from rare diseases. In addition, 60 ApoPharma employees will join the Group, which will allow the opening of offices in Toronto, Canada. The Chiesi Group has already been the distributor of Deferiprone for Apotex in some countries, including Italy, Brazil, and Turkey.
“The addition of Ferriprox® to our portfolio strengthens our offerings to patients and expands our commitment to the rare disease communities around the world. In addition, our presence in Canada represents an entirely new geography for our company and an important milestone in our continued focus on meeting the needs of patients around the world”, says Ugo Di Francesco, Chiesi Group CEO.Read the full Press Release